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Aims: The aim of this A1chieve sub-group analysis was to examine populations beginning
insulin aspart together with any basal insulin, all ± oral glucose lowering drugs: insulin
aspart added to existing basal insulin (n = 519); switched from biphasic insulin (n = 947);
switched from NPH plus human meal-time insulins (n = 586); and insulin-naïve begun with
basal plus insulin aspart (n = 1594).
Methods: A1chieve was a 24-week non-interventional study evaluating insulin analogues in
66,726 people with type 2 diabetes in routine clinical care in 28 non-Western countries.
Major endpoints were analysed as change from baseline using Student’s paired t-test.
Results: Baseline glycaemic control was poor (mean HbA1c: 9.4–10.1 % [79–87 mmol/mol]).
HbA1c, FPG and PPPG improved signiﬁcantly from baseline in all groups (mean change from
baseline in HbA1c: −2.8 to −1.8 % [−31 to −20 mmol/mol]; FPG: −4.9 to −2.9 mmol/L; PPPG:
−6.7 to −3.9 mmol/L; p < 0.001 for all), resulting in a similar level of blood glucose control
for all groups at study end. Unsurprisingly, hypoglycaemia rates increased in those starting
insulin, but decreased in the other groups. Clinically signiﬁcant improvements in serum
lipids and quality of life occurred across all groups.
Conclusions: These data support the use of basal plus prandial insulin regimens in routine
clinical practice in people with type 2 diabetes with inadequate glycaemic control.
1. Introduction
Type 2 diabetes is a progressive disease and insulin therapy
is needed in most people to ensure continuing adequacy of
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blood glucose control [1]. Initially, basal insulin can be effec-
tive in many people with type 2 diabetes for maintenance
of control, but in some people post-prandial glucose levels
remain elevated or will be elevated as endogenous insulin
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further declines. Addition of a meal-time insulin is con-
sequently indicated in order to provide better postprandial
glucose control. Controlling postprandial glucose is impor-
tant, even at high levels of HbA1c (>10.0 % [86 mmol/mol]),
when basal insulin has not been optimised, given that it can
contribute up to 30% of overall glucose control [2]. Adding
a meal-time insulin to basal insulin therapy is advocated by
type 2 diabetes treatment guidelines as a method that allows
the “most precise and ﬂexible” insulin regimen [3].
Insulin analogues have been designed to provide more
physiological pharmacokinetic/pharmacodynamic proﬁles
compared with conventional human insulins [4]. Rapid-
acting insulin analogues have a quicker onset and shorter
duration of action than unmodiﬁed human insulin [4], and
this has resulted in superior postprandial glucose control in
randomised controlled trials (RCTs) [5,6]. Insulin aspart is
one such rapid-acting insulin analogue. RCTs have shown it
to be well tolerated and effective in people with type 1 or
type 2 diabetes [7–9], but few studies have examined the use
of insulin aspart in routine clinical practice in people with
type 2 diabetes.
The A1chieve study investigated insulin analogue use in
people with type 2 diabetes across four continents in the
non-Western world [10], and recruited 66,726 participants.
The aim of the study was to expand the knowledge of the
clinical safety and effectiveness of insulin analogues in a
large and diverse population from a globally-broad variety of
clinical care situations; overall results of the A1chieve study
have been published previously [10,11].
In this A1chieve sub-group analysis, the aim was to
closely examine populations beginning insulin aspart to-
gether with any basal insulin. Because the study was so
large, useful numbers are available for many different sub-
groups.
2. Participants
The aim was to examine those who added insulin aspart
to existing basal insulin; those who switched from biphasic
insulin to basal plus insulin aspart; those who switched
from NPH insulin plus human soluble insulin to basal plus
insulin aspart; and those who were insulin-naïve and started
a basal plus insulin aspart regimen. In this sub-analysis, 1594
participants were insulin-naïve prior to the A1chieve study,
519 were using basal insulin alone (± oral glucose-lowering
drugs [OGLDs]), 947 premix insulin, 746 basal insulin plus
a meal-time human insulin (of whom 586 were using NPH
insulin plus meal-time human insulin), and 301 were using
other insulin regimens.
3. Materials and methods
3.1. Study design
The A1chieve study was a 24-week, prospective, interna-
tional, non-interventional observational study, conducted in
3166 centres across 28 countries in four continents other
than Western Europe and North America. Eligible partici-
pants were insulin-naïve or prior insulin users with type
2 diabetes starting or switching to basal insulin detemir,
biphasic insulin aspart, meal-time insulin aspart, alone or in
combination, all ± OGLDs [10,11].
The primary overall objective of the study was to de-
termine the incidence of serious adverse drug reactions
(SADRs), including major hypoglycaemic events, considered
related to the study insulin between baseline and ﬁnal visit.
Secondary safety and effectiveness assessments included
change in number of overall and nocturnal hypoglycaemic
events in the last 4 weeks before interim and ﬁnal visits,
compared with the last 4 weeks before baseline visit. Con-
ﬁrmed major, minor and nocturnal hypoglycaemic events
were as deﬁned previously [10]. Efﬁcacy assessments were
change in HbA1c, fasting plasma glucose (FPG), postpran-
dial plasma glucose (PPPG), body weight, systolic blood pres-
sure (SBP) and lipid proﬁle between baseline and ﬁnal visit.
Health-related quality of life (HRQoL) was measured using
the EQ-5D Questionnaire [12] at baseline and study end [11].
The sub-groups investigated for this analysis were: 1) par-
ticipants who were previously treated with a basal insulin
and then added meal-time insulin aspart; 2) participants
who were previously treated with a premix insulin and who
switched to a basal plus prandial insulin regimen including
insulin aspart as the meal-time insulin; 3) participants who
were previously treated with NPH insulin plus human un-
modiﬁed insulin as a meal-time insulin and who switched
to basal insulin plus insulin aspart; 4) participants who were
insulin-naïve who started a basal plus prandial insulin regi-
men including insulin aspart as the meal-time insulin. Data
for those insulin-naïve participants who started insulin as-
part alone have been previously published [11].
Continuous variables were summarised using descriptive
statistics and discrete variables were summarised using fre-
quency tables (n [%]). All statistical analyses were two-sided,
using a pre-speciﬁed 5% signiﬁcance level. Change from
baseline HbA1c, FPG, PPPG and blood lipids was analysed
using Student’s paired t-test. The data analysis was gener-
ated by Novo Nordisk using SAS software, Version 9.1.3 (Cary,
NC, USA).
4. Results
Participant characteristics are provided in Table 1. The
insulin-naïve group had a shorter duration of diabetes and
somewhat worse blood glucose control than the insulin-
experienced populations. Prior to the study, 79% of partic-
ipants in the insulin-naïve group, 80% of those previously
using basal insulin, 65% of those previously using premix
and 51% of those previously using NPH + meal-time human
insulin were taking OGLDs. At baseline, use of OGLDs was
45% in those who were insulin naïve, 55% in those previ-
ously using basal insulin, 51% in the premix group, and 50%
in the NPH + meal-time human insulin group.
4.1. Safety
No individual previously insulin naïve experienced a
SADR during the study; four SADRs were experienced in two
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Table 1 – Participant characteristics according to pre-study insulin therapy.
Insulin-naïve Insulin-experienced
Basal insulin Premix insulin NPH plus meal-time human insulin
n 1594 519 947 586
Male/female (%) 59.7/40.3 52.2/47.8 52.3/47.7 44.5/55.5
Age (years) 53.1 (12.7) 54.1 (12.2) 52.7 (14.5) 53.7 (12.7)
Body weight (kg) 74.1 (16.8) 78.9 (17.8) 78.6 (17.3) 81.3 (18.2)
BMI (kg/m2) 26.9 (5.4) 28.8 (6.7) 28.9 (6.1) 29.6 (6.0)
Duration of diabetes (years) 7.1 (6.1) 10.9 (6.3) 11.7 (7.1) 11.7 (6.9)
HbA1c (% / mmol/mol) 10.1 (2.1) / 87 (23) 9.7 (1.7) / 83 (19) 9.4 (1.7) / 79 (19) 9.4 (1.6) / 79 (17)
Values are mean (SD) unless otherwise noted.
BMI, body mass index.
people previously treated with human meal-time + basal in-
sulin (diabetic ketoacidosis and hypoglycaemia; and a fall
plus pelvic fracture); three SADRs were reported in three
people previously using only basal insulin (inadequate con-
trol of diabetes mellitus, hypoglycaemia, and hypoglycaemic
unconsciousness); and two people previously treated with
premix insulin reported hypoglycaemia as an SADR.
One person previously using basal insulin developed pan-
creatic carcinoma during the trial, and one previously using
NPH plus meal-time human insulin experienced angina pec-
toris. Otherwise no cardiac events or cancers were reported
as adverse events throughout the study period.
4.2. Insulin dose
Insulin-naïve participants started on a basal plus in-
sulin aspart regimen had a total insulin dose at day 1 of
0.60 U/kg/day, and at study end of 0.64 U/kg/day (Table 2).
Those starting from a basal plus meal-time human insulin
regimen started at 0.76 U/kg/day, then decreased slightly at
day 1 (0.73 U/kg/day) before increasing to 0.85 U/kg/day at
24 weeks. Insulin injection frequencies at pre-study, baseline
and study end are included in Table 3.
Approximately 80% of patients injected meal-time aspart
three times daily for the prior insulin-naïve, premix and
NPH plus meal-time human insulin sub-groups, and approx-
imately 70% of those who added insulin aspart to a basal
insulin. The majority of participants (84–93%) injected basal
insulin once daily in all groups, apart from those using NPH
plus meal-time human insulin prior to the study (63%).
4.3. Blood glucose control
Whether measured as HbA1c, FPG or PPPG the level of
blood glucose control reached at 24 weeks was strikingly
similar across all four insulin regimen groups in contrast
to baseline levels, which were highest in the insulin-naïve
population (mean HbA1c [SD] 10.1 [2.1] % [87 (23) mmol/mol])
and lowest in those on the human insulin multiple injec-
tion regimen (9.4 [1.6] % [79 (17) mmol/mol]) (Table 2). As a
result, in regressing to the same level, improvements were
greatest in the insulin-naïve group (mean HbA1c [SD] change
from baseline −2.8 [2.0] % (31 [22] mmol/mol); p < 0.001) and
smallest in the human multiple injection group (−1.8 [1.6] %
(20 [17] mmol/mol); p < 0.001). It was not otherwise apparent
that the groups starting with no prior meal-time insulin (i.e.
insulin-naïve and basal alone) saw greater relative postpran-
dial falls (mean PPPG [SD] change from baseline −6.7 [5.0]
mmol/L and −5.5 [4.4] mmol/L, respectively; p < 0.001 for
both) than the groups taking some meal-time insulin before-
hand (−5.7 [4.7] mmol/L for previous premix users and −3.9
[3.9] mmol/L for previous NPH plus meal-time human insulin
users; p < 0.001 for both).
4.4. Hypoglycaemia
In the four weeks before baseline, hypoglycaemia rates
of any kind were lowest in the insulin-naïve group (overall,
1.7 events per person-year) and highest in the multiple in-
sulin injection group (overall, 22.5 events per person-year)
(Table 2). These differences were much smaller in the four
weeks preceding 24 weeks, although the same pattern is dis-
cernible: while hypoglycaemia rates rose in those starting
insulin for the ﬁrst time (to 3.0 events per person-year), they
fell in the other groups (overall 3.3–4.4 events per person-
year. Overall rates in the ﬁnal period correspond to around
one event per 3–4 months on average, but 9–14% of parti-
cipants on any regimen had at least one event in the ﬁnal
4-week period (Table 2), suggesting that a small minority
of people accounted for most events. Severe hypoglycaemia
was very infrequent, barely registering in the 4-week ascer-
tainment periods at either baseline (range from 0.2 to 1.8
events per person-year) or 24 weeks (0.0 events per person-
year for all groups), but without any suggestion of an in-
crease (Table 2).
4.5. Body weight, blood lipids and blood pressure control
Those insulin-naïve participants starting a basal plus as-
part regimen did not gain or lose weight over the 24 weeks
of improved blood glucose control (mean [SD] change in
body weight from baseline −0.0 [4.2] kg; NS) (Table 2). Those
changing from another insulin regimen on average lost a
clinically insigniﬁcant amount of weight (−0.6 [3.9] kg; p =
0.004 for previous basal insulin users, −0.3 [3.5] kg; p = 0.043
for previous premix users, −0.4 [3.6] kg; p = 0.028 for previous
NPH plus meal-time human insulin users (Table 2). Serum
lipid proﬁle improved for all measures and for all insulin
groups, with clinically-useful improvements of around 10%
or more in total and LDL cholesterol, smallest in the group
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changing from the human insulin multiple injection regi-
men (mean [SD] change from baseline −0.4 [1.2] mmol/L;
p < 0.001, and −0.2 [1.2] mmol/L; p = 0.01, respectively)
(Table 2). Systolic BP also fell by clinically-useful amounts,
although it had not been particularly elevated overall at
Table 2 – Baseline and 24-week safety and effectiveness data for participants starting insulin aspart with basal insulin
by prior glucose-lowering regimen.
Outcome measure Prior glucose-lowering management
Insulin-naïve Insulin-experienced
Basal insulin Premix insulin NPH plus meal-time
human insulin
Insulin dose (U/kg/day) Pre-study – 0.40 (0.21) 0.68 (0.28) 0.76 (0.30)
Day 1 0.60 (0.25) 0.65 (0.25) 0.73 (0.28) 0.73 (0.29)
Week 24 0.64 (0.29) 0.71 (0.28) 0.81 (0.32) 0.85 (0.32)
HbA1c (%) Baseline 10.1 (2.1) 9.7 (1.7) 9.4 (1.7) 9.4 (1.6)
Week 24 7.3 (1.2) 7.4 (1.2) 7.4 (1.1) 7.5 (1.3)
Change −2.8 (2.0) −2.2 (1.7) −2.0 (1.7) −1.8 (1.6)
p-value <0.001 <0.001 <0.001 <0.001
HbA1c (mmol/mol) Baseline 87 (23) 83 (19) 79 (19) 79 (17)
Week 24 56 (13) 57 (13) 57 (12) 58 (14)
Change −31 (22) −24 (19) −22 (19) −20 (17)
p-value <0.001 <0.001 <0.001 <0.001
FPG (mmol/L) Baseline 11.9 (4.1) 10.3 (3.3) 10.5 (3.8) 10.0 (3.2)
Week 24 7.0 (1.7) 6.8 (1.6) 6.9 (1.8) 7.1 (2.0)
Change −4.9 (4.2) −3.4 (3.4) −3.7 (3.7) −2.9 (3.2)
p-value <0.001 <0.001 <0.001 <0.001
PPPG (post-breakfast) (mmol/L) Baseline 15.7 (5.0) 14.4 (4.1) 14.6 (4.7) 12.6 (4.1)
Week 24 9.0 (2.3) 8.9 (2.4) 8.9 (2.2) 8.7 (2.3)
Change −6.7 (5.0) −5.5 (4.4) −5.7 (4.7) −3.9 (3.9)
p-value <0.001 <0.001 <0.001 <0.001
Body weight (kg) Baseline 74.7 (16.9) 79.6 (17.3) 79.2 (16.0) 81.7 (17.7)
Week 24 74.6 (15.5) 79.0 (16.1) 79.0 (15.1) 81.3 (16.5)
Change −0.0 (4.2) −0.6 (3.9) −0.3 (3.5) −0.4 (3.6)
p-value NS 0.004 0.043 0.028
Total serum cholesterol (mmol/L) Baseline 5.6 (1.5) 5.4 (1.4) 5.2 (1.3) 5.6 (1.4)
Week 24 4.9 (1.0) 4.8 (1.0) 4.7 (0.9) 5.1 (1.1)
Change −0.7 (1.3) −0.5 (1.1) −0.5 (1.1) −0.4 (1.2)
p-value <0.001 <0.001 <0.001 <0.001
Serum triglycerides (mmol/L) Baseline 2.2 (1.2) 2.1 (1.1) 2.1 (1.1) 1.9 (1.0)
Week 24 1.7 (0.7) 1.7 (0.7) 1.8 (0.7) 1.7 (0.8)
Change −0.5 (1.0) −0.4 (0.9) −0.3 (0.8) −0.2 (0.8)
p-value <0.001 <0.001 <0.001 <0.001
Serum HDL-C (mmol/L) Baseline 1.2 (0.5) 1.1 (0.5) 1.1 (0.4) 1.2 (0.6)
Week 24 1.3 (0.4) 1.2 (0.4) 1.2 (0.3) 1.3 (0.5)
Change 0.1 (0.4) 0.1 (0.4) 0.1 (0.4) 0.1 (0.5)
p-value <0.001 0.076 <0.001 0.001
Serum LDL-C (mmol/L) Baseline 3.3 (1.1) 3.1 (1.0) 3.1 (1.0) 3.0 (1.1)
Week 24 2.8 (0.8) 2.7 (0.9) 2.7 (0.8) 2.8 (1.0)
Change −0.5 (1.0) −0.4 (0.8) −0.4 (0.9) −0.2 (1.2)
p-value <0.001 <0.001 <0.001 0.01
SBP (mmHg) Baseline 133.7 (18.1) 134.9 (16.9) 134.0 (18.1) 135.5 (18.5)
Week 24 127.6 (12.6) 130.2 (14.0) 128.4 (12.0) 130.0 (13.2)
Change −6.1 (15.7) −4.7 (15.6) −5.6 (14.9) −5.5 (15.8)
p-value <0.001 <0.001 <0.001 <0.001
QoL UK score Baseline 0.74 (0.25) 0.70 (0.23) 0.70 (0.26) 0.68 (0.21)
Week 24 0.84 (0.20) 0.81 (0.19) 0.82 (0.20) 0.82 (0.19)
Change 0.10 (0.25) 0.11 (0.24) 0.13 (0.26) 0.13 (0.22)
p-value <0.001 <0.001 <0.001 <0.001
QoL VAS score Baseline 65.6 (17.4) 63.2 (17.9) 64.3 (17.3) 59.8 (18.1)
Week 24 77.8 (12.0) 77.3 (11.7) 76.7 (12.9) 74.6 (14.3)
Change 12.2 (17.9) 14.1 (18.1) 12.4 (18.8) 14.9 (18.0)
p-value value <0.001 <0.001 <0.001 <0.001
baseline, with the biggest change observed in the insulin-
naïve group (mean [SD] change from baseline −6.1 [15.7]
mmHg; p < 0.001) (Table 2). Data are not available on the
use of lipid-lowering or anti-hypertensive therapy at the two
time points.
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Table 2 (continued)
Outcome measure Prior glucose-lowering management
Insulin-naïve Insulin-experienced
Basal insulin Premix insulin NPH plus meal-time
human insulin
Hypoglycaemia (events per person-year/% with event)
Overall Baseline 1.7/5.4 10.3/22.9 11.5/26.8 22.5/37.2
Week 24 3.0/8.7 3.3/10.3 3.4/11.1 4.4/13.5
Minor Baseline 1.5/5.4 9.2/22.2 10.2/25.2 20.7/36.2
Week 24 3.0/8.7 3.3/10.3 3.3/11.1 4.4/13.5
Nocturnal Baseline 0.4/1.8 4.5/12.9 3.5/13.4 6.5/19.6
Week 24 0.4/2.4 0.7/4.3 0.8/4.8 0.8/4.4
Major Baseline 0.2/0.6 1.1/4.8 1.3/6.5 1.8/7.0
Week 24 0.0/0.0 0.0/0.0 0.0/0.0 0.0/0.0
Values are mean (SD) unless otherwise noted.
FPG, fasting plasma glucose; PPPG, postprandial plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; SBP, systolic blood pressure; QoL, quality of life.
Table 3 – Insulin injection frequency in people starting insulin aspart with basal insulin by prior glucose-lowering
therapy.
Prior therapy Participants (%)
Meal-time insulin injection number Basal insulin injection number
One Two Three Three+ One Two Three
Insulin-naïve Day 1 8.3 11.0 80.3 0.4 90.0 9.9 0.2
Week 24 6.9 13.2 78.6 1.3 87.3 12.6 0.1
Basal insulin Pre-study – – – – 67.8 29.5 2.5
Day 1 14.7 18.3 66.6 0.4 84.4 15.3 0.2
Week 24 10.7 19.7 68.7 1.0 80.4 19.6 0.0
Premix insulin Pre-study (total) 2.5 92.4 5.0 0.1 – – –
Day 1 7.2 12.3 80.5 0.0 93.1 6.8 0.1
Week 24 6.2 14.2 78.8 0.7 92.3 7.7 0.0
NPH plus meal-time Pre-study 6.5 31.2 61.6 0.7 30.5 68.6 0.9
human insulin Day 1 5.6 14.5 79.1 0.7 62.7 37.1 0.2
Week 24 4.0 12.4 81.8 1.8 56.1 43.7 0.2
4.6. Health-related quality of life (HRQoL)
Baseline HRQoL scores were similarly impaired using both
scales (EQ-5D UK and EQ-5D VAS) across all therapy groups
(mean [SD] baseline VAS score ranged from 59.8 [18.1] to 65.6
[17.4]) (Table 2). By 24 weeks they had improved clinically
and statistically signiﬁcantly in all four groups (mean [SD]
change from baseline ranged from 12.2 [17.9] to 14.9 [18.0]),
and to similar levels (mean [SD] VAS scores at study end
ranged from 74.6 [14.3] to 77.8 [12.0]). Attained scores on
both measures corresponded to approximately an 80% best
possible HRQoL.
5. Discussion
Globally, excluding the Western world, adding insulin aspart
to a basal insulin or switching from a premix or a human
insulin-based regimen to insulin aspart plus a basal insulin
was associated with signiﬁcant improvements across all as-
pects of glycaemic control, however measured, and to similar
ﬁnal levels in this analysis. The same is true of those with no
previous insulin therapy starting insulin aspart plus a basal
insulin. Indeed, the results achieved seem similar despite ap-
parent differences in blood glucose control, so that the group
starting higher (the insulin-naïve group) had the greatest
falls, and those with marginally better but still poor control
at baseline (the human insulin multiple injection regimen),
the smallest. While the mean ﬁnal levels achieved are not to
conventional targets (e.g. HbA1c <53 mmol/mol (<7.0 %), this
is after only 24 weeks, and compared with baseline levels is
a clinically signiﬁcant improvement of some magnitude. It
seems reasonable to speculate that the conformity of the
24-week results simply reﬂects the broadly similar insulin
regimens then being used, participant characteristics not be-
ing very different apart from the 4-year shorter duration of
diabetes in the prior insulin-naïve group (Table 1).
As with the overall A1chieve study [10,11], these results
were attained without associated weight gain or increase in
hypoglycaemia. Good tolerability of the regimen(s) is con-
ﬁrmed by the health-related quality of life data, where the
ﬁnal levels are consistent with other reports of people with
type 2 diabetes in moderate blood glucose control [13], with
very useful improvements from baseline that presumably re-
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ﬂect participants’ poor metabolic control at that time and
possibly an associated neglect of health care. The circum-
stances in which people entering A1chieve had come to the
attention of the physicians who began the insulin therapy
are not known, and while some of the poor control may rep-
resent clinical inertia in ambulatory care [14–18], other parts
may have been the stimulus for referral to a specialist, or an
acute co-morbid disturbance resulting in hospitalisation.
Improvements in blood lipid proﬁle are known to occur
with improvements in blood glucose control secondary to
insulin [19], but changes of the order of magnitude seen here
generally were from much poorer glucose control again. This,
in addition to the improvement in SBP, together with the lack
of weight gain and absence of increase in hypoglycaemia
(except in the prior insulin-naïve population), suggests that
insulin analogue therapy may in general have been part of
a package of therapy offered by the physician and team.
Part of that package could have included enhancement of
other therapies, but baseline blood pressure was not high
enough to prompt changes in anti-hypertensive therapy in a
large part of our study population, suggesting that lifestyle
advice and patient education had perhaps been delivered as
well. Clearly, the message then would become the important
one: that starting insulin analogue therapy can represent
an opportunity for people in a state of neglected metabolic
control to improve their overall vascular risk proﬁle, though
of course that might be true of other interventions too.
Diabetes duration of >10 years in the group consisting of
prior insulin users is consistent with the need for a more
complex insulin regimen, given the progressive nature of
islet beta-cell dysfunction in type 2 diabetes [20]; however,
what is more unusual is the insulin-naïve sub-group treated
with a prandial plus basal insulin regimen ahead of multi-
ple OGLD therapy or a simpler insulin regimen. This might
have occurred if the patient had an acute need at the time
insulin was started (such as an in-patient), or if the extent of
blood glucose deterioration was judged to be marked by the
physician who saw the patient for the ﬁrst time. Treatment
guidelines do suggest that if a person with type 2 diabetes
presents with HbA1c >10.0 % (86 mmol/mol), then insulin
should be recommended early on, but our patient group was
>7 years from diagnosis [3]. Considering patients’ relatively
low BMI and SBP levels it is possible that latent autoimmune
diabetes of adulthood (LADA) was the case here, but given
the number of participants that were recruited in a short
period of time this seems unlikely to account for many. It is
more likely that our population included a large numbers of
Asians, for whom some greater degree of islet beta-cell func-
tion, and thus insulin deﬁciency, is believed to be signiﬁcant
in the pathogenesis of hyperglycaemia.
There are few RCTs in people with type 2 diabetes that
compare the use of insulin aspart with human insulin, both
combined with a basal insulin [21,22]. Treatment with in-
sulin aspart ± NPH insulin in a 3-month RCT of 231 people
with type 2 diabetes resulted in a mean (SD) HbA1c reduc-
tion of 0.91 (1.00) % compared with a 0.73 (0.87) % reduction
in participants treated with human insulin ± NPH insulin
(p = 0.025) [21]. PPPG levels were also improved to a greater
extent with insulin aspart compared with human insulin.
Mean pre-meal-time doses were similar for the two insulins
(10–13 U for insulin aspart and 10–14.5 IU for human in-
sulin) and there was no statistical difference between the
groups in hypoglycaemia. Improved PPPG control with in-
sulin aspart vs. human insulin both with NPH insulin was
also seen in a 12-week crossover study of 21 people with
type 2 diabetes [22], although there was no difference in
HbA1c between the two insulins. The 4-T Study – a 3-year
RCT in 708 insulin-naïve people with type 2 diabetes – did
investigate the addition of insulin aspart to insulin detemir:
mean HbA1c after 3 years was 6.9% (mean reduction of
1.2% from baseline), with a median rate of hypoglycaemia of
1.7 events/patient/year [9]. To our knowledge, this sub-group
analysis is the only available data examining beginning in-
sulin aspart with a basal insulin in routine clinical practice.
The large amount of data generated by the A1chieve study
has enabled the investigation of therapy and prior regimen
in our sub-groups, but there are limitations to consider when
interpreting these ﬁndings. Because the study was not ran-
domised, concomitant medications, patient education and
dietary behaviours may all have changed in concert with
use of the new insulin; indeed (see above), it seems likely
that this occurred. There may also have been a study effect,
even though the data were collected in routine clinical prac-
tice without pre-deﬁned visits or protocol driven care. Con-
founding could have occurred through regional differences
skewing the results, and limiting overall generalizability of
the ﬁndings; however, given the extent of the changes and
indeed the very limited changes for body weight and hypo-
glycaemia, it does not seem likely that changes in one or two
global continents could account for the changes in the whole
population reported here. Unfortunately, even with the num-
ber of participants in A1chieve, once selection is performed
for insulin then broken down into four subgroups, as here,
further segmentation by global region or country results in
numbers too small to be analytically reliable, and so was not
attempted.
In conclusion, this study provides further support for the
use of basal plus prandial insulin regimens in people with
type 2 diabetes with inadequate glycaemic control, at least
in the context of provision of other aspects of diabetes care.
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